Key result
Combined EMCV/PCV2 vaccine provides ~100% protection against lethal infections in pigs without immune interference.
Why the study?
Does a combination vaccine against EMCV and PCV2 induce protective immune responses in mice and swine?
Does a combination vaccine against EMCV and PCV2 induce protective immune responses in mice and swine?
Absolute Event Rate: 100% vs 0%
A novel combination vaccine against EMCV and PCV2 is safe and provides dual protection in swine, offering a potential strategy for disease management in pig farms.
Supports further preclinical development of combined swine vaccines; hypothesis-generating and should not yet change farm practice.
Encephalomyocarditis virus (EMCV) and porcine circovirus type 2 (PCV2) are common causative agents with high infection rate in pig farms, thus a combined vaccine against both EMCV and PCV2 is highly desirable. In the present study, we developed an oil-adjuvant combination vaccine candidate comprising of inactivated EMCV and PCV2, and evaluated the safety and immunogenicity in mice and swine. The combination vaccine was found to elicit serum antibodies and had strong neutralization activity, more importantly, passive immunization with the combined vaccine protected swine against either EMCV or PCV2 lethal infections, whereas the monovalent vaccine only prevent the one of two virus challenge. Our results demonstrated the combined vaccine was safe and induced protective immune response in mice and swine as evident from sero-conservation as well as challenge studies in swine, indicating that component vaccines did not interfere with the immunogenicity of each other.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2018) studied Encephalomyocarditis virus (EMCV) and porcine circovirus type 2 (PCV2) infection (n=76). Combined inactivated EMCV and PCV2 vaccine vs. PBS (un-vaccinated control) and monovalent vaccines was evaluated on Protection against virulent EMCV or PCV2 challenge in pigs. A combined inactivated vaccine against EMCV and PCV2 elicited strong neutralizing antibodies and provided 100% protection against both EMCV and PCV2 lethal infections in pigs, without immune interference.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: